Daiichi Sankyo to acquire Ambit Biosciences
Daiichi Sankyo and Ambit Biosciences jointly announced a merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash, or $315 million on a fully diluted basis. In addition, each Ambit stockholder will receive one CVR. September 29, 2014